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doi:10.1016/j.ejvs.2010.11.035Abstract Objective: One in four patients with primary iliofemoral deep vein thrombosis
(DVT) develops post-thrombotic syndrome (PTS) within 1 year despite optimal standard antico-
agulant therapy. Removal of thrombus by thrombolytic drugs may prevent PTS. The aim of this
study was to assess the short-term safety and efficacy of ultrasound-accelerated catheter-
directed thrombolysis (US-accelerated CDT).
Design: This was a prospective non-randomised interventional study with US-accelerated CDT
for DVT.
Patients and methods: Twelve patients with DVT (seven cavaleiliofemoropopliteal, three ilio-
femoropopliteal, one femoropopliteal and one superior caval vein thrombosis) receiving stan-
dard anticoagulant and compression therapy, were treated with additional US-accelerated CDT
(13 procedures) using the EKOS Endowave system (EKOS Corporation, Bothell, WA, USA)
between October 2008 and January 2010.
Results: Thrombolysis was successful in 85% (11/13), with complete clot lysis (>90% restored
patency) and in one case with partial clot lysis (50e90% restored patency). No pulmonary em-
bolism and one bleeding at the catheter-insertion site were observed. In three patients, under-
lying lesions were successfully treated with balloon angioplasty and stent insertion. Four
patients developed early recurrent thrombosis due to untreated residual venous obstruction.
Conclusion: US-accelerated CDT is a safe and promising treatment in patients with DVT. Residual
venousobstruction shouldbetreatedbyangioplastyandstent insertiontoavoidearly re-thrombosis.
ª 2010 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.41 8036070; fax: þ49 241 8082037.
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Catheter-directed Thrombolysis in DVT 527Patients with acute deep vein thrombosis (DVT) are treated haemorrhage in the previous year, severe hypertensionwith anticoagulation, compression therapy and mobilis-
ation.1 This standard DVT tripletherapy decreases mortality
by preventing life-threatening pulmonary embolism (PE)
and propagation of thrombosis, but has no direct throm-
bolytic effect. Re-canalisation and the preservation of
valve function, therefore, depend on the effectiveness of
the patient’s own fibrinolytic system. This has resulted in
high morbidity due to post-thrombotic syndrome (PTS).
Meissner et al. have demonstrated that valve function is
more likely to be retained after early clot lysis.2 Singh et al.
have revealed that the combination of obstruction and
reflux, rather than either one of these, significantly
increases the risk of developing PTS.3 Rapid clot dissolution
by early catheter-directed thrombolysis (CDT) before the
onset of valvular damage is suggested to be a way to
prevent the development of PTS.
A number of methods of CDT are currently available for
the treatment of DVT as outlined in a recent publication
from Pianta and Thomson.4 Motarjeme5 and Parikh et al.6
were the first to report ultrasound-accelerated (US-accel-
erated) CDT in DVT. They report significantly higher
complete clot lysis rates with US-accelerated CDT compared
with standard CDT,7 without raising bleeding or thrombo-
embolic risk. In vitro studies have demonstrated that high-
frequency, low-power microsonic energy improves lysis of
the thrombus considerably by increasing the uptake and
penetration of thrombolytic drugs into the thrombus.8,9 US-
accelerated CDT is effective in the treatment of peripheral
arterial occlusions,5 massive PE10 and acute ischaemic
stroke.11,12 Therefore, US-accelerated CDT may also be
a safe and promising candidate for immediate treatment of
DVT, having the benefits of thrombolysis combined with
minimising potential side effects. Few data are available
concerning the feasibility, safety and efficacy of US-accel-
erated CDT. Therefore, the aim of this study is to confirm
prospectively the short-term feasibility, safety and efficacy
of additional US-accelerated CDT in patients with DVT
treated using standard DVT therapy.
Materials and Methods
Patients
Between October 2008 and January 2010, 12 patients
(seven M: five F; median age 44 years (range 5e79)) with
symptomatic, duplex and computed tomography (CT)- or
magnetic resonance (MR) angiography confirmed DVT and
a life expectancy exceeding 6 months were treated with
US-accelerated CDT at the University Medical Centre
Maastricht (MUMCþ, the Netherlands), the University
Hospital RWTH Aachen (Germany) and the VU Medical
Centre Amsterdam (VUmc, the Netherlands). In five
patients, pulmonary embolism, which was confirmed by CT-
angiography, was present before the US-accelerated CDT
was commenced. One patient developed recurrent throm-
bosis 4 days after initial successful thrombolysis and
received a second thrombolytic procedure. Therefore, 13
cases of US-accelerated CDT were evaluated. Six patients
had a recurrent DVT. Exclusion criteria for US-accelerated
CDT were gastrointestinal bleeding or a cerebrovascular(>180/100 mm Hg), active malignancy, surgery in the
previous 6 weeks and/or pregnancy. In one case of upper-
extremity thrombosis, the innominate vein was also
involved. The 12 remaining cases involved lower-extremity
DVT. In those, the proximal end of the thrombosis reached
into the vena cava inferior in eight, the iliac vein in three
and the femoral vein in one case. The age of the thrombus
(defined as the number of days between the onset of
symptoms and the intervention) was 0e6 days (3/13), 7e13
days (5/13), 14e20 days (1/13) or  21 days (4/13) (Fig. 1).
Eligible patients received US-accelerated CDT with
recombinant tissue plasminogen activator (rtPA) (10/13) or
urokinase (3/13) combined with standard DVT therapy.
Anticoagulation was given according to international
guidelines (American College of Chest Physicians, 2008)
with the duration of planned treatment being 6 months for
idiopathic DVT and 3 months for provoked DVT.1 We
received approval or gained exemption for the collection of
data without patient identification from the institutional
review boards of the MUMCþ, the University Hospital RWTH
Aachen and the VUmc Amsterdam.
US-accelerated CDT
US-accelerated CDT was performed using the EKOS
Endowave system (EKOS Corporation, Bothell, WA, USA),
which combines a targeted-drug-delivery catheter with
high-frequency, low-power US energy (Fig. 2). This system
uses a standard 0.035-in. guide wire to position the 5.2-F
multi-lumen Intelligent Drug Delivery Catheter and match-
ing US coaxial core wires (with available treatment lengths
ranging from 6 to 50 cm) across the length of the target
clot. In all cases, the procedure was performed in an
interventional radiology suite. A 7-F sheath and a 0.035-in.
hydrophilic guide wire (Terumo Corporation, Shibuya-ku,
Tokyo, Japan) were placed with the assistance of US-guided
popliteal, femoral or jugular venous puncture. The cath-
eter was positioned along the guide wire using X-ray guid-
ance, with the end of the catheter at the proximal end of
the thrombus. The guide wire was then pulled out and
replaced by the Microsonic core containing a series of US
transducer elements (2 MHz, 0.45 W) distributed approxi-
mately 1.0 cm apart along its leading tip to deliver evenly
US energy radially along the coaxial infusion zone.
Thrombolysis
After priming the drug lumens of the catheter with heparin
(1000 IU), a single bolus of rtPA (5.0 mg) or urokinase
(500,000 IU) was administered by slow infusion. Afterwards,
continuous infusion of rtPA or urokinase was initiated
through the side-hole-delivery infusion catheter at a mean
rate of 1.0 mg h1 rtPA or 100,000 IU urokinase, respec-
tively. Simultaneously, normal saline solution was infused
as coolant through the central lumen of the catheter at
a rate of 35 ml h1. Thus, US energy was delivered through
the core wire with simultaneous infusion of the thrombo-
lytic drug. All patients were treated with an additional
continuous intravenous infusion of heparin through the
introducer sheath, which was monitored by assessment of
Figure 1 Age of thrombus versus success of thrombolysis This diagram shows there was no relation between the age of the
thrombus and the success of thrombolysis in this patient series. Successful thrombolysis includes complete and partial clot lysis,
defined as >90% and 50e90% restored venous patency respectively.
528 J. Grommes et al.the activated partial thromboplastin time (aPPT). Heparin
dosage was adjusted to obtain an aPTT ratio of 1.5e2.5.
Follow-up phlebograms were performed on all patients the
next day and at 24-h intervals thereafter.
Thrombolysis was terminated, if complete clot lysis was
achieved or the maximum infusion period of 72 h was
reached. Hourly and total infused rtPA and urokinase doses
and infusion times were recorded; additional angioplasty
with or without stent insertion was performed to treat
underlying lesions after thrombus lysis had been achieved.
Patients received their thrombolytic care at an intermediate
care unit and remained hospitalised for one night after
termination of thrombolytic treatment, if no complication
arose. After discharge, patients were followed up according
to the international guidelines for DVT therapy (ACCP 2008).1
Definitions
Thrombolysis success
Complete clot lysis was defined as >90% lysis (restored
patency), and partial clot lysis as 50e90% lysis (restored
patency) of the initial thrombus, as assessed on the final
phlebograms before additional procedures.
Bleeding
Bleeding was classified as major, if it was overt with a fall in
haemoglobin of 2 gd1, or when haemorrhage led to
transfusion of 2 units of packed red blood cells (RBCs) or
whole blood. Bleeding situated in a critical organ (intra-
cranial, retroperitoneal or pericardial) or, if it contributed
to death, was also defined as a major bleeding. Bleeding
was classified as minor, if it was situated near the catheter-
insertion site.
Follow-up
Every 3 months after discharge, all patients returned to the
outpatientdepartment for a follow-upvisit, includingclinicalinvestigation and duplex ultrasound examination to assess
the patency of treated vein segments and the extent of post-
thrombotic damage to the deep veins of the lower limb.
Results
Successful thrombolysis
Percutaneous catheterisation was successful in 12 proce-
dures, and, in one case, catheterisation of the popliteal
vein was achieved by open access.
Eleven out of 13 procedures (85%) resulted in complete
clot lysis (>90% restored patency). In one case, only partial
clot lysis (50e90% restored patency) was achieved. In one
case, thrombolysis was not successful.
The unsuccessful case involved a 5-year-old boy. He
developed DVT and PE as the consequence of a previously
undetected thrombophilia (Factor V Leiden) and immobili-
sation with a bilateral long-leg spica cast after orthopaedic
surgery.
Fig. 1 shows the age of the thrombus and the success of
thrombolysis. In this small study, no relationship was obs-
erved between successful thrombolysis and thrombus age.
Immediate adjunctive procedures
In three cases, underlying iliac vein stenosis was diagnosed
and successfully treated with balloon angioplasty and stent
insertion (60/16 mm Wallstent, 40/10 mm Nitinolstent
and 100/14 mm Wallstent, respectively) immediately
after thrombolysis. Fig. 2 shows the pre-, intra- and post-
thrombolysis phlebograms and the angioplasty with stent
insertion of one case involving a 36-year-old female patient
with iliocaval vein thrombosis.
Early recurrent thrombosis occurred in four cases of
which three were due to inadequate or no treatment of a
MayeThurner syndrome (common iliac vein stenosis) dem-
onstrated after completion of thrombolysis.
Figure 2 Pre-, intra-, post-thrombolysis and additional balloon angioplasty with stent insertion phlebograms Phlebographic
images from a 36-year old female patient who presented with a post-partum thrombosis from the femoral vein up to the inferior
caval vein (AeC). Follow-up phlebogram after 24 h US-accelerated CDT, showing a MayeThurner Syndrome (D.) and recanalised
iliac vein (D) and femoral Vein (E). After balloon angioplasty a Wallstent (diameter 16 mm, length 60 mm) was employed to
maintain patency of the treated vein (GeI).
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who developed a haematoma at the catheter-insertion site,
achieved by open access, and in the calf muscle, during
thrombolysis, necessitating a 50% reduction in the hourly
thrombolytic drug dose. Although the dose was reduced,
successful thrombolysis was achieved. Recurrent throm-
bosis occurred within a day due to a diagnosed but not
immediately treated MayeThurner syndrome. The throm-
bolytic therapy was not recommenced because of the
bleeding complication.
In the second case, which involved a 51-year-old male
patient, recurrent thrombosis developed 4 days after initial,
successful US-accelerated thrombolysis in whom the iliac
stenosis was not treated immediately. Thrombolysis was
repeated with success, followed by angioplasty and stenting
of the underlying MayeThurner syndrome and the construc-
tion of an arteriovenousfistula in the common femoral vein.In the third case, a 43-year-old male patient, recurrent
thrombosis occurred 1 day after successful thrombolysis, in
whom an underlying left-sided MayeThurner syndrome was
identified and inadequately treated with angioplasty alone
without stent placement.
In the fourth case, which involved a 52-year-old female
patient, recurrent thrombosis occurred 14 days after
successful US-accelerated CDT. This patient had a heparin-
induced thrombocytopenia (HIT type II) caused by enox-
aparin (Clexane).
Short-term follow-up
The mean follow-up period was 7 months (range 3e17). In
this period, no further occlusion of the venous system
occurred in the patients, who were discharged with a patent
venous system. In the 5-year-old boy with unsuccessful
Figure 3 Duplex images at 3-month follow-up of case presented in Fig. 2 The iliac vein with stent and femoral vein remained
patent at 3-month follow-up. (CIV Z common iliac vein, EIV Z external iliac vein, CFV Z common femoral vein, FV Z femoral
vein, FA Z femoral artery, DFV Z deep femoral vein).
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(spontaneous) re-canalisation of the inferior vena cava up to
the origin of the left renal vein. The iliac vein remained
occluded. In this patient, hypoplasia of the inferior vena cava
or a previous DVT probably caused failure of treatment.
In the 17-year-old girl with the untreated reocclusion
due to a bleeding complication and a MayeThurner
syndrome, 50% re-canalisation of femoral and iliac vein was
found after 6 months. Because she suffered from severe
venous claudication, the partially recanalised iliac vein was
successfully dilated and stented. Fig. 3 shows the duplex
images at 3 months of the case presented in Fig. 2.
The patient, who developed a reocclusion due to HIT
type 2, displayed 50% re-canalisation of the common iliac
and femoral veins at 6 months’ follow-up.
The iliac veins of the patient with the early reocclusion
after thrombolysis and angioplasty without stent placement
remained occluded during follow-up.
Complications
One (1/13; 8%) bleeding complication occurred at the site
of the catheter-insertion and in the calf muscle. NoPE was
diagnosed during or after the treatment. However, early re-
thrombosis was observed in four cases: one due to a HIT
type II and three due to an inadequate treatment of
residual venous obstruction.
Discussion
Standard DVT treatment focusses on adequate anti-
coagulation to prevent PE and thrombus propagation.
However, anticoagulation alone has no direct thrombolytic
effect. As a result, current DVT treatment often does notrestore venous patency, and venous valves are permanently
damaged. In addition, underlying venous stenoses such as
MayeThurner syndrome, which predispose to recurrent
thrombosis, are left untreated. The combination of venous
obstruction and reflux significantly increases the risk of
developing PTS.3 Therapy, which can remove the thrombus
and restore venous patency, may prevent recurrent
thrombosis and PTS.
Our study confirms the promising results of CDT for the
treatment of DVT. Most evidence regarding CDT for the
treatment of DVT is derived from patient series without
controls5,6,13 or cohort studies,7,14 and little evidence is
available from randomised clinical trials.15,16 Our study
obtained a 92% success rate and highlights the feasibility and
capability of the US-accelerated CDT. We observed no PE in
our patients during thrombolysis. Bleeding at the catheter-
insertion siteoccurred in onecase inwhomcatheterisationof
the popliteal vein was achieved by open access. Despite this
one case of bleeding, in whom we did not repeat thrombol-
ysis, no bleeding occurred during US-accelerated CDT.
However, four patients developed early recurrent
thrombosis after initial successful thrombolysis. In three
patients, underlying stenoses were identified which we
considered responsible for the recurrent thrombosis. In the
case in which the common iliac vein stenosis was only
treated by angioplasty resulting in early reocclusion,
a stent should have been inserted immediately to optimise
adequate flow in the iliac vein. The 17-year-old girl with
common iliac vein stenosis should have been treated
immediately by dilatation and stenting after successful
thrombolysis. In the third case, the same mistake was
made, but, luckily, this was corrected by repeat throm-
bolysis, stenting and insertion of an arteriovenous fistula.
These three cases highlight the need for immediate
treatment of all underlying obstructive lesions. After
Catheter-directed Thrombolysis in DVT 531successful re-canalisation of the venous system, residual
venous obstruction should be treated immediately by
means of angioplasty and stent insertion to avoid these
early reocclusions. Therefore, the centres treating those
patients should have the necessary stents immediately at
hand to perform these stent placements the moment the
underlying cause has been detected, even when throm-
bolysis has not been completed.
Similar findings have been reported by previous authors
such as the series reported in the National Venous Registry by
Mewissen et al.7 This registry data demonstrated that stan-
dard CDT with urokinase and additional stent placement
leads to complete (100%) clot lysis in 31% and partial
(50e99%) clot lysis in 52% of cases. The primary patency rate
for all patients in this registry was 65% and 60% at 6 and 12
months, respectively. These patency rates are similar to the
6-month patency rates reported for standard CDT combined
with anticoagulation, in two randomised controlled trials by
Elsharawy et al.15 and Enden et al.16 The degree of lysis was
found to be a significant predictor of early and continued
patency. In cases of complete clot lysis, 75% of veins
remained patent after 1 year, compared with only 32% of
veins in cases of insignificant (<50%) lysis. Moreover,
subgroup analysis revealed two important observations for
iliofemoral DVT: in the subgroup of patients with acute
primary iliofemoral DVT, 65% complete clot lysis was noted,
and 1-year patency in this complete lysis groupwas 96%. This
suggests that patients with iliofemoral DVT would benefit
most from CDT. In addition, Comerota et al.17,18 have
demonstrated that successful CDT in iliofemoral DVT signifi-
cantly improves quality of life (QoL) compared with failed
thrombolysis or anticoagulant therapy alone.
An additional advantage of CDT is the ability to detect and
treat underlying lesions (e.g., MayeThurner syndrome)
immediately after or during thrombolysis. Balloon dilatation
with or without stent placement improves long-term
patency,7,19 and can help prevent DVTor prolong the interval
to a recurrent DVT.4 Mewissen et al. have demonstrated that
adjunctive stent placement in the iliac vein significantly
improves patency: at 1 year, 74% of limbs treated with stent
placement after thrombolysis remained patent, compared
with only 53% of limbs without stent placement (P< 0.001).7
Bækgaard et al. more recently confirmed, in a large series of
patients (n Z 101), that additional stenting after CDT in
iliofemoral DVT results in excellent long-term patency rates
(82% patent veins at 6 years).19
Two previous series using US-accelerated CDT have
demonstrated considerably increased complete clot lysis
rates and fewer complications than standard CDT.5,6
Whereas only 31%7 of patients in the National Venous
Registry treated with standard CDT exhibited complete clot
lysis, 83%5 versus 85.7%6 of patients treated with US-
accelerated CDT using urokinase had complete clot lysis.
The major bleeding rate was 11% and the thrombo-embolic
rate 1%7 with standard CDT, compared with 0%5 to 3.8% and6
0%, respectively, in US-accelerated CDT.5,6Conclusion
US-accelerated CDT using EKOS Endowave was found to
be a feasible technique for managing iliofemoral venousthrombosis resulting in low morbidity and mortality. All
underlying obstructive vein lesions should be treated
immediately by venoplasty and stenting to prevent early
reocclusion. However, randomised controlled trails are
needed to evaluate the long-term benefit of endovenous
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